◼ Archived
Business
🔮 fades
Q32’s stock jumps 60% on latest phase 2 alopecia data for potential rival to JAK inhibitors
Q32 Bio (QTTB) shares surged following positive phase 2 clinical trial results for its alopecia areata drug, Bempikibart.